8 years of follow-up in the CheckMate 214 trial

Yüksel Ürün shared a paper by Nizar M. Tannir et al. on X:

“Nivolumab + ipilimumab (NIVO+IPI) shows superior overall survival and durable response compared to sunitinib (SUN) in advanced renal cell carcinoma (aRCC) patients after 8 years of follow-up in the CheckMate 214 trial.”

Source: Yüksel Ürün/X

Authors: N.M. Tannir, L. Albigès, D.F. McDermott, M. Burotto, T.K. Choueiri, H.J. Hammers, P. Barthélémy, E.R. Plimack, C. Porta, S. George, F. Donskov, M.B. Atkins, H. Gurney, C.K. Kollmannsberger, M.-O. Grimm, C. Barrios, Y. Tomita, D. Castellano, V. Grünwald, B.I. Rini, R. Jiang, H. Desilva, V. Federov, C.-W. Lee, R.J. Motzer

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.